What we know right now
Foundayo (orforglipron) was approved by the MHRA on 10 August 2026 — the first once-daily GLP-1 tablet with no fasting rules, covered in detail in our launch guide. On price, the honest answer is short: Eli Lilly has not announced UK pricing yet. Stock is expected to reach UK services in the coming weeks, and pricing confirmation is expected around launch. Any specific figure you see quoted before then is speculation.
What will shape the price
Some informed context is still possible. New weight-management medicines in the UK have launched at monthly price points broadly comparable with the existing injectable options, which private patients currently pay in the low-to-mid hundreds of pounds per month depending on dose and provider. Foundayo enters a market with established price expectations, direct competition from two licensed injectables, and a manufacturer with an interest in rapid adoption — all forces that argue against pricing far outside the familiar range.
The tablet format cuts some system costs — no cold-chain shipping, no sharps, simpler storage — though manufacturing, demand and commercial strategy will matter more to the sticker price than logistics savings. Where within (or beyond) the current range Lilly positions it is genuinely unknown until announced.
The US signal, for what it is worth
Foundayo launched in the United States earlier in 2026 following its FDA approval in April. US medicine pricing translates poorly to the UK — different systems, list-price conventions and discount structures — so we would caution against converting a dollar figure and calling it a forecast. The UK number will be its own announcement.
List prices, net prices and why both matter
Medicine pricing in the UK usually involves two numbers: a public list price, and confidential arrangements that determine what large purchasers actually pay. For patients, the list price shapes private prescription costs; for the NHS, the confidential net price is what NICE weighs against the medicine's benefits in deciding whether it is cost-effective. This is why a medicine can be judged too expensive for routine NHS use at one point and approved later after commercial negotiation — and why the NICE date in November matters commercially as well as clinically for Foundayo.
For budget-conscious readers, the practical takeaway while waiting: do not defer the eligibility conversation until the price appears. Consultations, medical history checks and treatment decisions take days; stock at launch will not wait for them. Being clinically assessed now costs nothing and turns the pricing announcement from the start of your process into the end of it.
Three scenarios worth planning for
Without a number, scenario thinking beats guessing. If Foundayo launches at a premium to the injectables, its market is convenience-first: people who will pay more to avoid needles, cold chains and weekly routines. If it prices level with them, the choice becomes almost purely clinical and preference-based, and demand will be intense against early stock. If it undercuts them, it pressures the whole category's pricing — good news for patients on every medicine in the class. Whichever lands, nothing about your eligibility changes: the consultation that qualifies you for one licensed treatment qualifies you to discuss all of them.
Tablet economics beyond the sticker price
A daily tablet also shifts small costs the sticker never shows. There is no sharps bin to arrange, no cold-chain delivery to be home for, no travel letters or cool bags for holidays, and a missed dose costs a day rather than disrupting a weekly cycle. Against that, daily adherence asks more of your routine than a weekly injection does, and treatment that is not taken consistently is the most expensive kind of all — money spent for diminished results. Factor your own habits honestly; they are part of the price.
Will it be available on the NHS?
Not at launch. NICE has a technology appraisal scheduled for 18 November 2026, and routine NHS funding depends on that outcome — which itself turns on the confidential price the NHS would pay. Until then, Foundayo will be a private-prescription medicine, accessed through regulated pharmacies after a clinician consultation, exactly like the injectable treatments today. Our guide to NHS eligibility explains how that system works for this class.
One more variable specific to tablets: pack sizes and dose tiers. Injectables price per pen at a given strength; a daily tablet's pricing structure — per pack, per dose tier, whether titration packs differ from maintenance packs — has its own geometry that affects monthly cost as your dose changes. How Lilly structures this will shape real-world affordability as much as the headline number, and it is one of the details we will break down the day pricing is published.
What previous launches suggest about the first months
The recent pattern in this market is consistent enough to plan around. New weight-management medicines have launched into intense demand with constrained early stock; early private access concentrated with providers who secured supply; prices and availability then settled as manufacturing scaled. Wegovy and Mounjaro both followed versions of this curve in the UK. If Foundayo does the same, the first weeks may involve waiting lists and dose-availability quirks even at the announced price — worth knowing so that early friction reads as normal launch mechanics rather than a reason to try unregulated channels, which will predictably exploit the gap.
A brief timeline recap for orientation: MHRA approval on 10 August 2026; UK stock expected from late August; pricing confirmation expected around launch; NICE appraisal scheduled 18 November 2026; NHS availability contingent on that outcome. Our launch guide covers the clinical detail; this page will track the money.
How to think about value when the price lands
When the number arrives, compare it the way we recommend for any weight-loss treatment price: the all-in monthly cost at your dose including consultations and delivery, over a realistic treatment duration. A tablet adds its own considerations — no injection training, easier travel, daily rather than weekly routine — which some people will value highly and others will not. Convenience is worth paying for only if it is convenience you will use.
We will update our guides when official UK pricing is announced. If you want to be treatment-ready for launch — or to start on a licensed option now rather than waiting — a free consultation with a UK-registered clinician establishes eligibility that carries across whichever medicine ends up right for you. Our weight-management guides cover the whole landscape.